HURA
XNAS
Market cap82mUSD
Nov 20, Last price
1.25USD
1D
-8.09%
1Q
-37.50%
IPO
-99.95%
Name
Kintara Therapeutics Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Kintara Therapeutics, Inc. operates as a clinical-stage biotechnology firm, dedicated to pioneering and commercializing anti-cancer treatments for patients. Central to its pipeline are two compounds nearing Phase III trials. One, VAL-083, is a DNA-targeting agent developed to combat drug-resistant solid tumors, including challenging conditions like glioblastoma multiforme, alongside other solid tumor types such as ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma. The other, REM-001, is a photodynamic therapy specifically targeting cutaneous metastatic breast cancer. The company has forged a strategic alliance with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to facilitate the production and sale of VAL-083 within the Chinese market. Incorporated in 2009, Kintara maintains its headquarters in San Diego, California. Its current identity as Kintara Therapeutics, Inc. was adopted in August 2020, succeeding its former name, DelMar Pharmaceuticals, Inc.
Key people
James Bianco
Chief Executive Officer, Director · since 2024
Dan Dearborn
Chief Financial Officer · since 2024
John Liatos
Senior Vice President, Business Development · since 2021
Dennis Yamashita
Chief Scientific Officer · since 2024
Director · since 2024
Alan List
Independent Director · since 2024
James Manuso
Independent Director · since 2024
George Ng
Independent Director · since 2024
Craig Tendler
Independent Director · since 2025
Legal address
C/O NEVADA AGENCY AND TRANSFER COMPANY
50 WEST LIBERTY STREET SUITE 880
RENO, NV 89501
US
50 WEST LIBERTY STREET SUITE 880
RENO, NV 89501
US
Headquarters
50 WEST LIBERTY STREET SUITE 880
RENO, NV 89501
US
RENO, NV 89501
US
Previous name
Berry Only Inc.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2024‑06 | 2023‑12 | 2023‑06 | 2022‑12 | 2022‑06 | 2021‑12 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | |||||||||||||
Revenues | |||||||||||||
Cost of revenue | |||||||||||||
Unusual Expense (Income) | |||||||||||||
NOPBT | |||||||||||||
NOPBT Margin | |||||||||||||
Operating Taxes | |||||||||||||
Tax Rate | |||||||||||||
NOPAT | |||||||||||||
Net income | |||||||||||||
Dividends | |||||||||||||
Dividend yield | |||||||||||||
Proceeds from repurchase of equity | |||||||||||||
BB yield | |||||||||||||
| Debt | |||||||||||||
Debt current | |||||||||||||
Long-term debt | |||||||||||||
Deferred revenue | |||||||||||||
Other long-term liabilities | |||||||||||||
Net debt | |||||||||||||
| Cash flow | |||||||||||||
Cash from operating activities | |||||||||||||
CAPEX | |||||||||||||
Cash from investing activities | |||||||||||||
Cash from financing activities | |||||||||||||
FCF | |||||||||||||
| Balance | |||||||||||||
Cash | |||||||||||||
Long term investments | |||||||||||||
Excess cash | |||||||||||||
Stockholders' equity | |||||||||||||
Invested Capital | |||||||||||||
ROIC | |||||||||||||
ROCE | |||||||||||||
| EV | |||||||||||||
Common stock shares outstanding | |||||||||||||
Price | |||||||||||||
Market cap | |||||||||||||
EV | |||||||||||||
EBITDA | |||||||||||||
EV/EBITDA | |||||||||||||
Interest | |||||||||||||
Interest/NOPBT | |||||||||||||